PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder
The aim of the study was to investigate the efficacy and safety of inhaled loxapine compared with the intramuscular (IM) antipsychotic aripiprazole in acutely agitated patients with schizophrenia or bipolar I disorder. PLACID was an assessor-blind, parallel-group trial conducted in 23 centres in the Czech Republic, Germany, Spain, and Russia. Patients (aged 18 –65 years) diagnosed with schizophrenia or bipolar I disorder experiencing acute agitation (Clinical Global Impression [CGI]-Severity score ≥ 4) while hospitalized or attending an emergency room were randomized to receive up to two doses of inhaled loxapine 9.1 mg or IM aripiprazole 9.75 mg (≥ 2 h between doses) during the 24-h study period.
Source: European Neuropsychopharmacology - Category: Psychiatry & Psychology Authors: Luis San, Gemma Estrada, Natalia Oudovenko, Francisco Monta ñés, Natalia Dobrovolskaya, Olga Bukhanovskaya, Mikhail Popov, Eduard Vieta Source Type: research
More News: Abilify | Bipolar | Brain | Czechia Health | Emergency Medicine | Eyes | Germany Health | Mania | Neurology | Psychology | Russia Health | Schizophrenia | Spain Health | Study